Impact of a Sequential Isokinetic Fatigue Protocol Followed by Ankle Strengthening After Botulinum Toxin Injection Into Spastic Plantar Flexors on Foot Lift Strength and Walking

NCT ID: NCT07260565

Last Updated: 2025-12-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-01

Study Completion Date

2028-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Spastic foot drop (speed- and force-dependent hypertonia) is one of the most common neuro-orthopaedic disorders following brain injury. It has a negative impact on walking and is closely linked to independence in activities of daily living.

This disorder combines a deficit in muscle strength in the plantar flexors and extensors with pathological hypertonia of the plantar flexors, causing an imbalance in ankle flexion and resulting in equinus deformity of the foot.

Botulinum toxin is the first-line pharmacological treatment for focal spasticity of neurological origin, and its effectiveness is directly linked to the quality and quantity of associated rehabilitation care. However, the associated rehabilitation protocols remain vague and are based on general recommendations combining: stretching of muscles and tendons, muscle strengthening of spastic muscles, their agonists and antagonists, and functional work. The standard rehabilitation protocol used in our centre will be detailed in the study protocol.

The isokinetic dynamometer is an open-chain muscle strengthening tool that has the advantage of introducing a concept of reproducible assessment and rehabilitation.

This reproducibility is difficult to guarantee with the rehabilitation techniques practised by a therapist, whose applied force and precision may vary from one session to another. We have therefore developed a sequential muscle strengthening protocol combining strengthening work - fatigue of the triceps surae followed by muscle strengthening work of the foot lifters.

The aim of this work is to determine the effects of this protocol compared to conventional rehabilitation aimed at promoting the post-injection effects of botulinum toxin.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spasticity of the Plantar Flexors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

standard rehabilitation protocol

Patients in this groupe will undergo a standard rehabilitation programme five times a week, Monday to Friday, combining physiotherapy and adapted physical activity.

Group Type OTHER

standard rehabilitation programme

Intervention Type PROCEDURE

Patients in group will undergo a standard rehabilitation programme five times a week, Monday to Friday, combining physiotherapy and adapted physical activity.

isokinetic rehabilitation protocol

Patients in this group will undergo isokinetic rehabilitation five times a week, Monday to Friday, and will receive treatment combining physiotherapy, adapted physical activity (see standard rehabilitation protocol) and strengthening on an isokinetic dynamometer.

Group Type EXPERIMENTAL

Isokinetic rehabilitation protocol.

Intervention Type PROCEDURE

Patients in group will undergo isokinetic rehabilitation therapy five times a week, Monday to Friday, combining physiotherapy, adapted physical activity (see standard rehabilitation protocol) and strengthening exercises on an isokinetic dynamometer.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Isokinetic rehabilitation protocol.

Patients in group will undergo isokinetic rehabilitation therapy five times a week, Monday to Friday, combining physiotherapy, adapted physical activity (see standard rehabilitation protocol) and strengthening exercises on an isokinetic dynamometer.

Intervention Type PROCEDURE

standard rehabilitation programme

Patients in group will undergo a standard rehabilitation programme five times a week, Monday to Friday, combining physiotherapy and adapted physical activity.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient
* Patient with spastic hemiplegia (regardless of cause)
* MAS 1-2 spasticity of the plantar flexors
* Deficit of the foot lifters at the minimum stage of contraction with movement
* Patient who has received botulinum toxin injections in the plantar flexors
* Patient who has been informed about the research and has given their written and signed informed consent
* Patient affiliated with a social security scheme or beneficiary of such a scheme

Exclusion Criteria

* Refusal of consent
* Patient with severe cognitive impairment (MMSE \<23/30)
* Surgery on the affected lower limb
* Patient unable to read, write or understand French
* Patient who is pregnant or breastfeeding, in accordance with Article L1121-5 of the CSP
* Vulnerable patients according to Article L1121-6 of the CSP
* Adult patients under guardianship, curatorship or judicial protection
* Patients unable to give their consent in person according to Article L.1121-8 of the CSP or adults protected by law
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Clinique Victor Pauchet

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Aurélie DUSSAUSSOY, Clinical research associated

Role: CONTACT

03 22 33 74 78

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-A00591-48

Identifier Type: OTHER

Identifier Source: secondary_id

2025-A00591-48

Identifier Type: -

Identifier Source: org_study_id